Etelcalcetide: A new drug for secondary hyperparathyroidism of chronic kidney disease
10.7501/j.issn.1674-6376.2017.03.028
- VernacularTitle:伊特卡赛肽:治疗慢性肾病继发性甲状旁腺机能亢进新药
- Author:
Fei ZHENG
;
Yanli ZHANG
;
Qian ZHANG
;
Ying GONG
;
Yuanyuan GU
;
Guodong HUA
- Keywords:
Etelcalcetide;
second generation calcimimetic agent;
chronic kidney disease;
secondary hyperparathyroidism;
parathyroid
- From:
Drug Evaluation Research
2017;40(3):428-432
- CountryChina
- Language:Chinese
-
Abstract:
Etelcalcetide (ParsabivTM) is a second generation calcimimetic agent newly developed by Amgen,mainly used for the treatment of secondary hyperparathyroidism.Etetcalcetide not only decreases calcium concentration by directly binding with the calcium sensing receptor,but also reduces the parathyroid hormone level.The European Union has approved for chronic kidney disease patients with secondary hyperparathyroidism in dialysis with Etelcalcetide injection.This paper summarized the pharmacological effects,pharmacokinetics,clinical trials,and adverse reaction of Etelcalcetide.
